All Outputs (3)

Comparison of Echo Planar and Turbo Spin Echo Diffusion‐Weighted Imaging in Intraoperative MRI (2024)
Journal Article
Thorpe, J. C., Thust, S. C., Gillon, C. H., Rowe, S., Swain, C. E., MacArthur, D. C., Howarth, S. P., Avula, S., Morgan, P. S., & Dineen, R. A. (2024). Comparison of Echo Planar and Turbo Spin Echo Diffusion‐Weighted Imaging in Intraoperative MRI. Journal of Magnetic Resonance Imaging, https://doi.org/10.1002/jmri.29614

Background: Diffusion-weighted imaging (DWI) is routinely used in brain tumor surgery guided by intraoperative MRI (IoMRI). However, conventional echo planar imaging DWI (EPI-DWI) is susceptible to distortion and artifacts that affect image quality.... Read More about Comparison of Echo Planar and Turbo Spin Echo Diffusion‐Weighted Imaging in Intraoperative MRI.

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article
Cornell, I., Al Busaidi, A., Wastling, S., Anjari, M., Cwynarski, K., Fox, C. P., Martinez-Calle, N., Poynton, E., Maynard, J., & Thust, S. C. (2023). Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy. Journal of Personalized Medicine, 13(7), Article 1182. https://doi.org/10.3390/jpm13071182

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021)
Journal Article
Fox, C. P., Ali, A. S., McIlroy, G., Thust, S., Martinez-Calle, N., Jackson, A. E., …Cwynarski, K. (2021). A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20), 4073-4082. https://doi.org/10.1182/bloodadvances.2021004779

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.